Correction: "Human cytosolic extracts stabilize the HIV-1 core" [Journal of Virology, 87, 19, (2013) (10587-10597)] doi 10.1128/JVI.01705-13;Human cytosolic extracts stabilize the HIV-1 core

Journal of Virology

Volumn 87, Issue 19, 2013, Pages 10587-10597

  Fricke, Thomas ^a   Brandariz Nuñez, Alberto ^a   Wang, Xiaozhao ^b   Smith, Amos B ^b   Diaz Griffero, Felipe ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (4,5 DIPHENYL 1H IMIDAZOL 2 YL)BENZOIC ACID; ANTIRETROVIRUS AGENT; BI 2; CAP 1; CELL EXTRACT; CYCLOPHILIN A; CYCLOSPORIN; HUMAN CYTOSOLIC EXTRACT; HUMAN IMMUNODEFICIENCY VIRUS 1 CA NC COMPLEX; I XW 053; ISOLEUCYLTHREONYLPHENYLALANYLGLUTAMYLASPARTYLLEUCYLLEUCYLASPARTYLTYROSYLTYROSYLGLYCYLPROLINE; ISOLEUCYLTYROSYLASPARTYLPROPYLTHREONYLLEUCYLTYROSYLGLYCYLLEUCYLGLUTAMYLPHENYLALANYLASPARTIC ACID; N (3 CHLORO 4 METHYLPHENYL) N' [2 [[[5 [(DIMETHYLAMINO)METHYL] 2 FURYL]METHYL]SULFANYL]ETHYL]UREA; PF 3450074; PROTEIN CPSF6[1-321]; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ANIMAL CELL; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG SENSITIVITY; DRUG TARGETING; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IN VITRO STUDY; MACROMOLECULAR CROWDING; NONHUMAN; PRIORITY JOURNAL; PROTEIN ASSEMBLY; VIRUS CAPSID; VIRUS CORE;

HUMAN IMMUNODEFICIENCY VIRUS 1; MIRIDAE;

EID: 84886075852     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.01732-17     Document Type: Erratum

References (48)

1. Suzuki Y, Craigie R. 2007. The road to chromatin: nuclear entry of retroviruses. Nat. Rev. Microbiol. 5:187-196.
2. Li L, Olvera JM, Yoder KE, Mitchell RS, Butler SL, Lieber M, Martin SL, Bushman FD. 2001. Role of the non-homologous DNA end joining pathway in the early steps of retroviral infection. EMBO J. 20:3272-3281.
3. Butler SL, Hansen MS, Bushman FD. 2001. A quantitative assay for HIV DNA integration in vivo. Nat. Med. 7:631-634.
4. Briggs JA, Simon MN, Gross I, Krausslich HG, Fuller SD, Vogt VM, Johnson MC. 2004. The stoichiometry of Gag protein in HIV-1. Nat. Struct. Mol. Biol. 11:672-675.
5. Briggs JA, Wilk T, Welker R, Krausslich HG, Fuller SD. 2003. Structural organization of authentic, mature HIV-1 virions and cores. EMBO J. 22: 1707-1715.
6. Lanman J, Lam TT, Emmett MR, Marshall AG, Sakalian M, Prevelige PE, Jr. 2004. Key interactions in HIV-1 maturation identified by hydrogen-deuterium exchange. Nat. Struct. Mol. Biol. 11:676-677.
7. Fassati A, Goff SP. 2001. Characterization of intracellular reverse transcription complexes of human immunodeficiency virus type 1. J. Virol. 75:3626-3635.
8. McDonald D, Vodicka MA, Lucero G, Svitkina TM, Borisy GG, Emerman M, Hope TJ. 2002. Visualization of the intracellular behavior of HIV in living cells. J. Cell Biol. 159:441-452.
9. Arfi V, Lienard J, Nguyen XN, Berger G, Rigal D, Darlix JL, Cimarelli A. 2009. Characterization of the behavior of functional viral genomes during the early steps of human immunodeficiency virus type 1 infection. J. Virol. 83:7524-7535.
10. Diaz-Griffero F, Kar A, Lee M, Stremlau M, Poeschla E, Sodroski J. 2007. Comparative requirements for the restriction of retrovirus infection by TRIM5alpha and TRIMCyp. Virology 369:400-410.
11. Hulme AE, Perez O, Hope TJ. 2011. Complementary assays reveal a relationship between HIV-1 uncoating and reverse transcription. Proc. Natl. Acad. Sci. U.S.A. 108:9975-9980.
12. Roa A, Hayashi F, Yang Y, Lienlaf M, Zhou J, Shi J, Watanabe S, Kigawa T, Yokoyama S, Aiken C, Diaz-Griffero F. 2012. RING domain mutations uncouple TRIM5alpha restriction of HIV-1 from inhibition of reverse transcription and acceleration of uncoating. J. Virol. 86:1717-1727.
13. Stremlau M, Perron M, Lee M, Li Y, Song B, Javanbakht H, Diaz-Griffero F, Anderson DJ, Sundquist WI, Sodroski J. 2006. Specific recognition and accelerated uncoating of retroviral capsids by the TRIM5alpha restriction factor. Proc. Natl. Acad. Sci. U.S.A. 103:5514-5519.
14. Diaz-Griffero, F. 2012. The role of TNPO3 in HIV-1 replication. Mol. Biol. Int. 2012:868597. doi:10.1155/2012/868597.
15. Yamashita M, Emerman M. 2004. Capsid is a dominant determinant of retrovirus infectivity in nondividing cells. J. Virol. 78:5670-5678.
16. Yamashita M, Emerman M. 2006. Retroviral infection of non-dividing cells: old and new perspectives. Virology 344:88-93.
17. Yamashita M, Perez O, Hope TJ, Emerman M. 2007. Evidence for direct involvement of the capsid protein in HIV infection of nondividing cells. PLoS Pathog. 3:1502-1510.
18. Forshey BM, von Schwedler U, Sundquist WI, Aiken C. 2002. Formation of a human immunodeficiency virus type 1 core of optimal stability is crucial for viral replication. J. Virol. 76:5667-5677.
19. Ohagen A, Gabuzda D. 2000. Role of Vif in stability of the human immunodeficiency virus type 1 core. J. Virol. 74:11055-11066.
20. Yang Y, Fricke T, Diaz-Griffero F. 2013. Inhibition of reverse transcriptase activity increases stability of the HIV-1 core. J. Virol. 87:683-687.
21. Berube J, Bouchard A, Berthoux L. 2007. Both TRIM5alpha and TRIMCyp have only weak antiviral activity in canine D17 cells. Retrovirology 4:68.
22. De Iaco A, Santoni F, Vannier A, Guipponi M, Antonarakis S, Luban J. 2013. TNPO3 protects HIV-1 replication from CPSF6-mediated capsid stabilization in the host cell cytoplasm. Retrovirology 10:20.
23. Diaz-Griffero F, Kar A, Perron M, Xiang SH, Javanbakht H, Li X, Sodroski J. 2007. Modulation of retroviral restriction and proteasome inhibitor-resistant turnover by changes in the TRIM5alpha B-box 2 domain. J. Virol. 81:10362-10378.
24. Diaz-Griffero F, Perron M, McGee-Estrada K, Hanna R, Maillard PV, Trono D, Sodroski J. 2008. A human TRIM5alpha B30.2/SPRY domain mutant gains the ability to restrict and prematurely uncoat B-tropic murine leukemia virus. Virology 378:233-242.
25. Forshey BM, Shi J, Aiken C. 2005. Structural requirements for recognition of the human immunodeficiency virus type 1 core during host restriction in owl monkey cells. J. Virol. 79:869-875.
26. Ohkura S, Goldstone DC, Yap MW, Holden-Dye K, Taylor IA, Stoye JP. 2011. Novel escape mutants suggest an extensive TRIM5alpha binding site spanning the entire outer surface of the murine leukemia virus capsid protein. PLoS Pathog. 7:e1002011. doi:10.1371/journal.ppat.1002011.
27. Perron MJ, Stremlau M, Lee M, Javanbakht H, Song B, Sodroski J. 2007. The human TRIM5alpha restriction factor mediates accelerated uncoating of the N-tropic murine leukemia virus capsid. J. Virol. 81:2138-2148.
28. Shi J, Zhou J, Shah VB, Aiken C, Whitby K. 2011. Small-molecule inhibition of human immunodeficiency virus type 1 infection by virus capsid destabilization. J. Virol. 85:542-549.
29. Ganser BK, Li S, Klishko VY, Finch JT, Sundquist WI. 1999. Assembly and analysis of conical models for the HIV-1 core. Science 283:80-83.
30. Brandariz-Nunez A, Menaya-Vargas R, Benavente J, Martinez-Costas J. 2010. A versatile molecular tagging method for targeting proteins to avian reovirus muNS inclusions. Use in protein immobilization and purification. PLoS One 5:e13961. doi:10.1371/journal.pone.0013961.
31. White TE, Brandariz-Nunez A, Carlos Valle-Casuso J, Amie S, Nguyen L, Kim B, Brojatsch J, Diaz-Griffero F. 2013. Contribution of SAM and HD domains to retroviral restriction mediated by human SAMHD1. Virology 436:81-90.
32. Ellis RJ. 2001. Macromolecular crowding: an important but neglected aspect of the intracellular environment. Curr. Opin. Struct. Biol. 11:114-119.
33. Ellis RJ. 2001. Macromolecular crowding: obvious but underappreciated. Trends Biochem. Sci. 26:597-604.
34. Sticht J, Humbert M, Findlow S, Bodem J, Muller B, Dietrich U, Werner J, Krausslich HG. 2005. A peptide inhibitor of HIV-1 assembly in vitro. Nat. Struct. Mol. Biol. 12:671-677.
35. Ganser-Pornillos BK, Cheng A, Yeager M. 2007. Structure of full-length HIV-1 CA: a model for the mature capsid lattice. Cell 131:70-79.
36. Lepage O, Bhardwaj P, Faucher A, Grand-Maître C, Lacoste J, Lamorte L, Mercier J. 24 November 2011. Inhibitors of HIV replication. US patent WO 2011/143772 A1.
37. Kortagere S, Madani N, Mankowski MK, Schon A, Zentner I, Swaminathan G, Princiotto A, Anthony K, Oza A, Sierra LJ, Passic SR, Wang X, Jones DM, Stavale E, Krebs FC, Martin-Garcia J, Freire E, Ptak RG, Sodroski J, Cocklin S, Smith AB, III. 2012. Inhibiting early-stage events in HIV-1 replication by small-molecule targeting of the HIV-1 capsid. J. Virol. 86:8472-8481.
38. Kelly BN, Kyere S, Kinde I, Tang C, Howard BR, Robinson H, Sundquist WI, Summers MF, Hill CP. 2007. Structure of the antiviral assembly inhibitor CAP-1 complex with the HIV-1 CA protein. J. Mol. Biol. 373:355-366.
39. Tang C, Loeliger E, Kinde I, Kyere S, Mayo K, Barklis E, Sun Y, Huang M, Summers MF. 2003. Antiviral inhibition of the HIV-1 capsid protein. J. Mol. Biol. 327:1013-1020.
40. Blair WS, Pickford C, Irving SL, Brown DG, Anderson M, Bazin R, Cao J, Ciaramella G, Isaacson J, Jackson L, Hunt R, Kjerrstrom A, Nieman JA, Patick AK, Perros M, Scott AD, Whitby K, Wu H, Butler SL. 2010. HIV capsid is a tractable target for small molecule therapeutic intervention. PLoS Pathog. 6:e1001220. doi:10.1371/journal.ppat.1001220.
41. Fricke T, Valle-Casuso JC, White TE, Brandariz-Nunez A, Bosche WJ, Reszka N, Gorelick R, Diaz-Griffero F. 2013. The ability of TNPO3-depleted cells to inhibit HIV-1 infection requires CPSF6. Retrovirology 10:46.
42. Li J, Tan Z, Tang S, Hewlett I, Pang R, He M, He S, Tian B, Chen K, Yang M. 2009. Discovery of dual inhibitors targeting both HIV-1 capsid and human cyclophilin A to inhibit the assembly and uncoating of the viral capsid. Bioorg. Med. Chem. 17:3177-3188.
43. Luban J. 2007. Cyclophilin A, TRIM5, and resistance to human immunodeficiency virus type 1 infection. J. Virol. 81:1054-1061.
44. Luban J, Bossolt KL, Franke EK, Kalpana GV, Goff SP. 1993. Human immunodeficiency virus type 1 Gag protein binds to cyclophilins A and B. Cell 73:1067-1078.
45. Rits MA, van Dort KA, Kootstra NA. 2008. Polymorphisms in the regulatory region of the cyclophilin A gene influence the susceptibility for HIV-1 infection. PLoS One 3:e3975. doi:10.1371/journal.pone.0003975.
46. Sokolskaja E, Luban J. 2006. Cyclophilin, TRIM5, and innate immunity to HIV-1. Curr. Opin. Microbiol. 9:404-408.
47. Li Y, Kar AK, Sodroski J. 2009. Target cell type-dependent modulation of human immunodeficiency virus type 1 capsid disassembly by cyclophilin A. J. Virol. 83:10951-10962.
48. Lamorte L, Titolo S, Lemke CT, Goudreau N, Mercier J-F, Wardrop E, Shah VB, von Schwedler UK, Langelier C, Banik SS, Aiken C, Sundquist WI, Mason SW. Discovery of novel small-molecule HIV-1 replication inhibitors that stabilize capsid complexes. Antimicrob. Agents Chemother., in press.